Neurent Medical announced that Cigna Healthcare will now cover its Neuromark system for chronic rhinitis treatment, removing CPT 31242 posterior nasal nerve ablation using radiofrequency (RF) from its Experimental & Investigational list, effective September 15.
Galway-based Neurent designed Neuromark to target posterior nasal nerves with real-time feedback, guiding proper electrode placement and confirming treatment success. The system’s flexible shaft and atraumatic leaflets help physicians navigate complex nasal anatomy, while impedance-controlled RF energy disrupts parasympathetic nerve signals—addressing chronic nasal congestion and runny nose.
Neurent’s CEO, Brian Shields, highlighted that the policy shift removes barriers for ENT specialists and expands patient access to minimally invasive chronic rhinitis care. The update follows close collaboration with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) to advance adoption of posterior nasal nerve ablation in the U.S.
Follow MEDWIRE.AI for updates on ENT treatment innovations and payer coverage breakthroughs.
